Archives of Pharmacal Research

, Volume 24, Issue 6, pp 514–517 | Cite as

Virus-cell fusion inhibitory activity for the polysaccharides from various Korean edible clams

Research Article Medicinal Chemistry & Natural Products

Abstract

In order to find potent virus-cell fusion inhibitory components from Korean edible clams, thirteen prepared polysaccharides were introduced to syncytia formation inhibition assay, which is based on the interaction between the HIV-1 envelope protein gp120/41 and the cellular membrane protein CD4 of T lymphocytes. Among them,Meretrix petechialis showed a potent viruscell fusion inhibitory activity. Fusion index (FI) and percent (%) fusion inhibition of the polysaccharide of this clam were 0.21 ±0.02, and 67.52±4.09 at 100μg/ml, respectively. It exhibited almost equivalent virus-cell fusion inhibitory activity to that of dextran sulfate which was used as a standard control.

Key words

Anti-HIV gp120/41 Syncytia Fusion Clams 

References

  1. Amornrut, C., Toida, T., Imanari, T., Woo, E. -R., Park, H., Linhardt, R., Wu, S. J., Kim, Y. S., A new sulfated β-galactan from clams with anti-HIV activity.Carbohydr. Res. 32, 121–7 (1999).CrossRefGoogle Scholar
  2. Cheserbo, B., and Wehrly, K., Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.J. Virol., 62, 3779–3788 (1988).Google Scholar
  3. De Clercq, E., Suramin in the treatment of AIDS: mechanism of action.Antiviral Res., 7, 1–10 (1987).PubMedCrossRefGoogle Scholar
  4. De Clercq, E., HIV resistance to reverse transcriptase inhibitors.Biochem. Pharmacol., 47, 155–169 (1994).PubMedCrossRefGoogle Scholar
  5. De Clercq, E., Antiviral therapy for human immunodeficiency virus infections.Clin. Microbiol. Rev., 8, 200–239 (1995).PubMedGoogle Scholar
  6. Earl, P. L., Hugin, A. W., and Moss, B., Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.J. Virol., 64, 2448–2451 (1990).PubMedGoogle Scholar
  7. Faulds, D., and Brogden, R. N., Didanosine. a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.Drugs, 44, 94–116 (1992).PubMedCrossRefGoogle Scholar
  8. Hart, T. K., Kirsh, R., Ellens, H., Sweet, R. W., Lambert, D. M., Petteway, S. R., Leary, J., and Bugelski, P. J., Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.Proc. Natl. Acad. Sci. USA, 88, 2189–2193 (1991).PubMedCrossRefGoogle Scholar
  9. Kim, Y. S., Jo, Y. Y., Chang, I. -M., Toida, T., Park, Y. M. Linhardt, R. J., A New Glycosaminoglycan from the Giant African Snail fromAchatina fulica.J. Biol. Chem., 271, 1750–11755 (1996).Google Scholar
  10. Kim, H. J., Woo, E. -R., Shin, C. -G., and Park, H., A new flavonol glycoside gallate fromAcer okamotoanum and its inhibitory activity against human immunodeficiency virus (HIV) integrase.J. Nat. Prod., 61, 145–148 (1998).PubMedCrossRefGoogle Scholar
  11. Kim, H. J., Lee, J. S., Woo, E. -R., Kim, M. K., Yang, B. S., Yu, Y. G., Park, H., and Lee, Y. S., Isolation of virus-cell fusion inhibitory components fromEugenia caryophyllata.Planta med., 67, 99–102 (2001).PubMedCrossRefGoogle Scholar
  12. Langtry, H. D., and Campoli-Richards, D. M., Zidobudine, a review of its pharmacodynamic and pharmacokinetic properities, and therapeutic efficacy.Drugs, 37, 408–450 (1989).PubMedCrossRefGoogle Scholar
  13. Lin, P. -F., Samanta, H., Bechtold, C. M., Deminie, C. A., Patick, A. K., Alam, M., Riccardi, K., Rose, R. E., White, R. J., and Colonno, R. J., Characterization of siamycin l, a human immunodeficiency virus fusion inhibitor.Antimicrob.Agents Chemother., 40, 133–138 (1996).Google Scholar
  14. Mayaux, J. -F., Bousseau, A., Pauwels, R., Huet, T., Henin, Y., Dereu, N., Evers, M., Soler, F., Poujade, C., De Clercq, E., and Le Pecq, J. -B., Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.Proc. Natl. Acad. Sci. USA, 91, 3564–3568 (1994).PubMedCrossRefGoogle Scholar
  15. Nakashima, H., Ichiyama, K., Inazawa, K., Ito, M., Hayashi, H., Nishihara, Y., Tsujii, E., and Kino, T., FR901724, a novel anti-human immunodeficiency virus (HIV) peptide produced by Streptomyces, shows synergistic antiviral activities with HIV protease inhibitor and 2, 3-dideoxy-nucleosides.Biol. Pharm. Bull., 19, 405–412 (1996).PubMedGoogle Scholar
  16. Pereira, F. B., Goni, F. M., and Nieva, J. L., Liposome dest-abilization induced by the HIV-1 fusion peptide effect of a single amino acid substitution.FEBS Letters, 362, 243–246 (1995).PubMedCrossRefGoogle Scholar
  17. Ryu, J. -R., Jin, B. -S., Suh, M. -J., Yoo, Y. -S., Yoon, S. H., Woo, E. -R., and Yu, Y. G., Two interaction modes of the gp41 -derived peptides with gp41 and their correlation with antimembrane fusion activity.Biochem. Biophys. Res. Commun., 265, 625–629 (1999).PubMedCrossRefGoogle Scholar
  18. Ryu, J. -R., Lee, J., Choo, S., Yoon, S. H., Woo, E. -R., and Yu, Y. G., Development of an in vitro assay system for screening of gp 41 inhibitory compounds.Mol. Cells., 8, 717–723 (1998).PubMedGoogle Scholar
  19. Tochikura, T. S., Nakashima, H., Tanabe, A., Yamamoto, N., Human immunodeficiency virus (HlV)-induced cell fusion: Quantification and its application for the simple and rapid screening of anti-HIV substances in vitro.Virol., 164, 542–546 (1988).CrossRefGoogle Scholar
  20. Whittington, R., and Brogden, R. N., Zalcitabine, a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).Drugs, 44, 656–683 (1992).PubMedCrossRefGoogle Scholar
  21. Woo, E. -R., Yoon, S. H., Kwak, J. H., Kim, H. J., and Park, H., Inhibition of gp120-CD4 interaction by various plant extracts.Phytomedicine, 4, 53–58 (1997).Google Scholar
  22. Wu, S. J., Chun, M. W., Shin, K. H., Toida, T., Park, Y., Linhardt, R. J., and Kim, Y. S., Chemical oversulfation and anticoagulant activity of acharan sulfate.Thromb. Res., 92, 273–281 (1998).PubMedCrossRefGoogle Scholar
  23. Yao, X-J., Wainberg, M. A., and Parniak, M. A., Mechanism of inhibition of HIV-1 in vitro by purified extracts ofPrunella vulgaris.Virol., 187, 56–62 (1992).CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2001

Authors and Affiliations

  1. 1.College of PharmacyChosun UniversityKwangjuKorea
  2. 2.Natural Products Research InstituteSeoul National UniversitySeoulKorea

Personalised recommendations